US › Healthcare

Cerenome, Inc. (CNSY)

US · Healthcare · Biotechnology

$0.64-4.46%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$411,000

Revenue YoY

-70.4%

Net profit

$-9.0M

Profit YoY

-274.8%

EPS

$-1.31

EPS estimate

$-0.96

Net margin

-2,191.2%

EPS came in at -1.31 against a street estimate of -0.96 — a miss of 36.5%.

Key statistics

Market cap

$5.1M

Forward P/E

1.0

P/B

1.81

Book value

$0.75

EPS (TTM)

$-3.36

52-week high

$19.00

52-week low

$0.60

50-day MA

$2.01

200-day MA

$4.54

Beta

1.47

Analyst view

Analysts rate Cerenome, Inc. a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $27.75.

Shareholding

Insiders

1.98%

Institutions

15.71%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	4.02%
BlackRock Inc	1.26%
Geode Capital Management, LLC	1.00%
Vanguard Fiduciary Trust Co	0.49%
State Street Corp	0.41%
Citadel Advisors Llc	0.34%
Northern Trust Corp	0.20%
Virtu Financial LLC	0.20%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cerenome, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.